The pharmacokinetics of orally administered butylscopolamine in greyhound dogs
The oral tablet formulation of butylscopolamine, which is available without prescription, is commonly used by trainers of racing greyhounds to treat functional urethral obstruction. As medication control of butylscopolamine is therefore required for such use to ensure the integrity of greyhound raci...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018
|
| Online Access: | https://eprints.nottingham.ac.uk/53420/ |
| _version_ | 1848798937045008384 |
|---|---|
| author | Morris, Tim Paine, Stuart Viljanto, Marjaana Hudson, Simon Gower, Simon Pittorino, Melissa Colgan, Sally |
| author_facet | Morris, Tim Paine, Stuart Viljanto, Marjaana Hudson, Simon Gower, Simon Pittorino, Melissa Colgan, Sally |
| author_sort | Morris, Tim |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | The oral tablet formulation of butylscopolamine, which is available without prescription, is commonly used by trainers of racing greyhounds to treat functional urethral obstruction. As medication control of butylscopolamine is therefore required for such use to ensure the integrity of greyhound racing an administration study was performed in six greyhounds to determine the pharmacokinetics of orally administered butylscopolamine. A single dose of one 10 mg butylscopolamine tablet was administered orally to simulate this use in greyhound racing. Blood, urine and faeces were collected at regular intervals from the greyhounds for up to 9 days and butylscopolamine concentrations determined. There was some, but very limited, absorption of butylscopolamine, with rapid elimination from plasma with a mean half-life of 2 hours. Urine concentrations initially declined in a similar manner to the plasma pharmacokinetics but then entered a much longer half-life of approximately 50 hours. Faecal concentrations declined to very low levels between 48 and 120 hours. The use of orally administered butylscopolamine for functional urethral obstruction in greyhounds is unjustified due this very limited drug absorption. Medication control of butylscopolamine’s anti-spasmodic effect on the digestive tract is possible by setting screening limits based on the urinary and faecal drug levels as determined in this study. |
| first_indexed | 2025-11-14T20:27:42Z |
| format | Article |
| id | nottingham-53420 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T20:27:42Z |
| publishDate | 2018 |
| publisher | Wiley |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-534202019-08-03T04:30:13Z https://eprints.nottingham.ac.uk/53420/ The pharmacokinetics of orally administered butylscopolamine in greyhound dogs Morris, Tim Paine, Stuart Viljanto, Marjaana Hudson, Simon Gower, Simon Pittorino, Melissa Colgan, Sally The oral tablet formulation of butylscopolamine, which is available without prescription, is commonly used by trainers of racing greyhounds to treat functional urethral obstruction. As medication control of butylscopolamine is therefore required for such use to ensure the integrity of greyhound racing an administration study was performed in six greyhounds to determine the pharmacokinetics of orally administered butylscopolamine. A single dose of one 10 mg butylscopolamine tablet was administered orally to simulate this use in greyhound racing. Blood, urine and faeces were collected at regular intervals from the greyhounds for up to 9 days and butylscopolamine concentrations determined. There was some, but very limited, absorption of butylscopolamine, with rapid elimination from plasma with a mean half-life of 2 hours. Urine concentrations initially declined in a similar manner to the plasma pharmacokinetics but then entered a much longer half-life of approximately 50 hours. Faecal concentrations declined to very low levels between 48 and 120 hours. The use of orally administered butylscopolamine for functional urethral obstruction in greyhounds is unjustified due this very limited drug absorption. Medication control of butylscopolamine’s anti-spasmodic effect on the digestive tract is possible by setting screening limits based on the urinary and faecal drug levels as determined in this study. Wiley 2018-08-03 Article PeerReviewed application/pdf en https://eprints.nottingham.ac.uk/53420/1/Pharmacokinetics%20of%20orally%20administered%20butylscopolamine%20in%20greyhound%20dogs%20accepted.pdf Morris, Tim, Paine, Stuart, Viljanto, Marjaana, Hudson, Simon, Gower, Simon, Pittorino, Melissa and Colgan, Sally (2018) The pharmacokinetics of orally administered butylscopolamine in greyhound dogs. Journal of Veterinary Pharmacology and Therapeutics . ISSN 1365-2885 https://onlinelibrary.wiley.com/doi/abs/10.1111/jvp.12701 doi:10.1111/jvp.12701 doi:10.1111/jvp.12701 |
| spellingShingle | Morris, Tim Paine, Stuart Viljanto, Marjaana Hudson, Simon Gower, Simon Pittorino, Melissa Colgan, Sally The pharmacokinetics of orally administered butylscopolamine in greyhound dogs |
| title | The pharmacokinetics of orally administered butylscopolamine in greyhound dogs |
| title_full | The pharmacokinetics of orally administered butylscopolamine in greyhound dogs |
| title_fullStr | The pharmacokinetics of orally administered butylscopolamine in greyhound dogs |
| title_full_unstemmed | The pharmacokinetics of orally administered butylscopolamine in greyhound dogs |
| title_short | The pharmacokinetics of orally administered butylscopolamine in greyhound dogs |
| title_sort | pharmacokinetics of orally administered butylscopolamine in greyhound dogs |
| url | https://eprints.nottingham.ac.uk/53420/ https://eprints.nottingham.ac.uk/53420/ https://eprints.nottingham.ac.uk/53420/ |